Yahoo
KOSDAQ - Delayed Quote KRW

ABL Bio Inc. (298380.KQ)

39,750.00 +550.00 (+1.40%)
At close: 3:30:13 PM GMT+9
Chart Range Bar
Loading chart for 298380.KQ
  • Previous Close 39,200.00
  • Open 38,900.00
  • Bid 39,800.00 x --
  • Ask 39,750.00 x --
  • Day's Range 38,600.00 - 40,350.00
  • 52 Week Range 38,250.00 - 257,500.00
  • Volume 224,072
  • Avg. Volume 329,769
  • Market Cap (intraday) 2.226T
  • Beta (5Y Monthly) 0.38
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 270,000.00

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.

www.ablbio.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

298380.KQ
80.13%
KOSPI Composite Index (^KS11)
39.03%

1-Year Return

298380.KQ
60.13%
KOSPI Composite Index (^KS11)
42.64%

3-Year Return

298380.KQ
140.47%
KOSPI Composite Index (^KS11)
150.05%

5-Year Return

298380.KQ
68.43%
KOSPI Composite Index (^KS11)
94.43%

Analyst Insights

View More

Analyst Price Targets

260,000.00
270,000.00 Average
39,750.00 Current
280,000.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -229.36%

  • Return on Assets (ttm)

    -20.78%

  • Return on Equity (ttm)

    -44.26%

  • Revenue (ttm)

    34.28B

  • Net Income Avi to Common (ttm)

    -78.63B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    167.08B

  • Total Debt/Equity (mrq)

    31.88%

  • Levered Free Cash Flow (ttm)

    -29.08B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: